Clinical Trial Update: Study Evaluating CCI-779 in Relapsing Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating CCI-779 (temsirolimus) in relapsing multiple sclerosis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Temsirolimus (temsirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED